Floatz logo

Loxo-338

Lymphoma, B-cell Marginal Zone

Eli Lilly and CompanyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

105 Active assets in the Lymphoma, B-cell Marginal Zone cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Loxo-338 is also rated in:

mantle cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CC
Indicative ·
41 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →